Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
asset sale
Biotech
Amylyx seeks to fill Relyvrio-sized hole with $35M GLP-1 buy
Searching for a path forward after the withdrawal of Relyvrio in ALS, Amylyx has bought a GLP-1 receptor antagonist from Eiger for $35.1 million.
Annalee Armstrong
Jun 24, 2024 10:18am
AngioDynamics sheds some catheter products in $45M deal
Feb 16, 2024 10:37am
Basilea anti-infective strategy restarts with $2M antifungal buy
Oct 19, 2023 7:25am
Novo Nordisk buys rival to Bayer's Kerendia in $1.3B deal
Oct 16, 2023 9:30am
Impel works to stave off bankruptcy, puts itself up for sale
Oct 5, 2023 11:16am
Thea drops ProQR eye asset purchase after staff refuse to move
Sep 27, 2023 12:38pm
